Mirum Pharmaceuticals

General Information
Business:

 

We are a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. We focus on diseases for which the unmet medical need is high and the biology for treatment is clear. Our pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of orphan liver diseases. We are initially developing maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 24
Founded: 2018
Contact Information
Address 950 Tower Lane, Suite 1050, Foster City, CA 94404, US
Phone Number (650) 667-4085
Web Address http://www.mirumpharma.com
View Prospectus: Mirum Pharmaceuticals
Financial Information
Market Cap $345.2mil
Revenues $0 mil (last 12 months)
Net Income $-23.3 mil (last 12 months)
IPO Profile
Symbol MIRM
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $16.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Citigroup/ Evercore ISI/ Guggenheim Securities
CO-Managers Raymond James/ Roth Capital Partners
Expected To Trade: 7/18/2019
Day: Thursday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change